Durvalumab with cisplatin and etoposide

Author: wbuo

August undefined, 2024

WebAug 13, 2024 · A 74-year-old man exhibited lack of efficacy during treatment with cisplatin and etoposide for lung large cell neuroendocrine carcinoma (L-LCNEC). Additionally, he … WebMay 25, 2024 · Background: In extensive stage small-cell lung cancer (ES-SCLC) immune check-point inhibitors, atezolizumab and durvalumab, when combined with …

A Phase III, Randomized, Open-Label, Multi-Center, Global Study …

WebNov 14, 2024 · Durvalumab is used to treat cancer of the lungs, bladder, or urinary tract. Durvalumab is sometimes given when the cancer has spread to other parts of the body … Webo Weight 30 kg and more: With etoposide and either carboplatin or cisplatin, administer IMFINZI 1500 mg every 3 weeks in combination with chemotherapy, and then 1500 mg every 4 weeks as a single agent (2.1) o Weight less than 30 kg: With etoposide and either carboplatin or cisplatin, administer IMFINZI 20 mg/kg every 3 weeks in porthcawl cctv

Durvalumab, with or without tremelimumab, plus …

WebIntroduction. Patients with stage III non-small cell lung cancer (NSCLC) are treated with platinum-based doublet chemotherapy and radiotherapy; however, chemoradiation alone has a poor prognosis [Citation 1].Adjuvant durvalumab after chemoradiation has become the standard of care for patients with stage III NSCLC, according to the PACIFIC trial … WebApr 11, 2024 · Two phase 3 trials evaluated the addition of programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab (IMpower133) (5, 6) or durvalumab (CASPIAN) (7, 8) to … WebMar 30, 2024 · Mar 30, 2024. Gina Columbus. The FDA has approved durvalumab for the first-line treatment of adult patients with extensive-stage small cell lung cancer for use in combination with standard-of-care ... porthcawl charity shop

BC Cancer Protocol Summary for Treatment of Extensive …

Durvalumab - NCI - National Cancer Institute

WebFeb 6, 2024 · Patients were randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab + etoposide and platinum-based chemotherapy (EP), durvalumab + EP or EP alone. 987 participants were randomized in the study overall. ... (80-100 mg/m^2) with either carboplatin (area under the curve 5-6) or cisplatin (75-80 … WebCisplatin 75-80 1 Q3W 4 Etoposide 100 1-3 Q3W 4 Durvalumab 1500 mg 1 Q4W maintenance 藥品名劑量 mg/m2 給藥日頻率週期參考文獻 Durvalumab 1500 mg 1 Q3W 4 10 Carboplatin AUC 5-6 1 Q3W 4 Etoposide 100 1-3 Q3W 4 Durvalumab 1500 mg 1 Q4W maintenance 藥品名劑量 mg/m2 給藥日頻率週期參考文獻 Cisplatin 75-80 1 … porthcawl centreWebA Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Bladder Cancer porthcawl chinese

"Webcarboplatin or cisplatin for nonsquamous cell histology; OR Used in combination with tremelimumab-actl, gemcitabine, and either ... Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label ... " - Durvalumab with cisplatin and etoposide

Durvalumab with cisplatin and etoposide

Durvalumab Uses, Side Effects & Warnings - Drugs.com

WebJan 17, 2024 · Day 1: Durvalumab 1,500mg IV over 60 minutes, followed by: Day 1: Carboplatin AUC 5-6 IV over 30 minutes Days 1-3: Etoposide 80-100mg/m 2 IV over 60 … WebFeb 28, 2024 · The EP regimen (etoposide plus cisplatin), in particular, ... CASPIAN, aimed to explore the efficacy of the anti–PD-L1 antibody durvalumab and the anti–CTLA …

Did you know?

WebDec 4, 2024 · First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide) showed a significant improvement in overall survival versus … WebOct 26, 2024 · Durvalumab group: Cisplatin (75 mg/m² (BSA) D1#) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 1.8-2 Gy/d with start at latest at beginning of cycle 3, ideally during cycle 1) and additional Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles according to …

WebThe patient underwent one cycle of induction chemotherapy with cisplatin and etoposide. Positron-emission tomography/computed tomography (PET-CT) after induction chemotherapy showed the tumor increased in size. The patient received volumetric modulated arc therapy (VMAT) with simultaneous integrated boost (SIB) and the … WebApr 11, 2024 · Two phase 3 trials evaluated the addition of programmed cell death-ligand 1 (PD-L1) inhibitor atezolizumab (IMpower133) (5, 6) or durvalumab (CASPIAN) (7, 8) to first-line chemotherapy (etoposide and cisplatin [EP]) followed by maintenance PD-L1 inhibitor in patients with ES-SCLC, and showed a significant improvement in overall survival (OS ...

WebApr 7, 2024 · Background In the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved OS versus EP alone in patients with extensive-stage (ES)-SCLC (HR 0.73 [95% CI 0.59–0.91; p = 0.0047]). Here we report results for a preplanned subgroup analysis of patients … WebSep 25, 2024 · Standard-of-care first-line treatment for extensive-stage small-cell lung cancer is platinum chemotherapy (carboplatin or cisplatin) with etoposide. 1-3 Despite response rates of 60 to 65%,...

WebOct 29, 2024 · As reported in The Lancet by Luis Paz-Ares, MD, and colleagues, an interim analysis of the phase III CASPIAN trial has shown an overall survival benefit with the …

WebFeb 28, 2024 · The EP regimen (etoposide plus cisplatin), in particular, ... CASPIAN, aimed to explore the efficacy of the anti–PD-L1 antibody durvalumab and the anti–CTLA-4 antibody tremelimumab combined with chemotherapy in the first-line treatment of patients with ES-SCLC. The study included patients with untreated ES-SCLC who were randomly … porthcawl christmas marketWebDec 5, 2024 · Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung … porthcawl caravans for saleWebMar 9, 2024 · In CASPIAN, patients receiving durvalumab with etoposide and either cisplatin or carboplatin also demonstrated improved OS (HR, 0.73; 95% CI, 0.59–0.91; … porthcawl christmas day swim 2021WebMay 30, 2024 · Durvalumab was administered at 1500 mg and tremelimumab was dosed at 75 mg. In all study arms, patients received etoposide at 80 to 100 mg/m² on days 1 to 3 of each 21-day cycle, with investigator’s choice of either carboplatin area under the curve 5 to 6 mg/mL per minute or cisplatin at 75 to 80 mg/m² administered on day 1 of each cycle. 1,4 porthcawl christmasWebDec 7, 2024 · Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive disease with poor survival, and platinum-etoposide chemotherapy is indicated as the mainstay of treatment. In this study, we compared the efficacy and safety between the cisplatin plus etoposide (EP) and carboplatin plus etoposide (EC) regimens. Methods porthcawl cf36WebMar 1, 2024 · Experimental: Durvalumab - (cisplatin or carboplatin) - Etoposide Participants will receive durvalumab dose A administered via intravenous (IV) … porthcawl christmas swim 2021WebIn combination with etoposide and either carboplatin or cisplatin, as first-line treatment for adults with extensive-stage small cell lung cancer. In combination with gemcitabine and … porthcawl chiropractor